secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANGIODYNAMICS INC (ANGO)
CIK:        0001275187
Form:       8-K
Filed at:   2022-04-07T23:59:59+00:00
Accession:  0000914121-22-002826
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AngioDynamics Q3 net sales $74.0M (+3.9% YoY); GAAP EPS -$0.13, adjusted $0.03; reaffirms FY guidance
--------------------------------------------------------------------------------

- Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.
- Gross margin 52.2%, down 190bps YoY on inflation, labor, supply chain; net loss $5.0M ($0.13/sh) vs $3.5M loss prior year.
- Adjusted EPS $0.03 (incl. $4.2M CARES Act benefit); adjusted EBITDA $6.7M vs $5.4M a year ago.
- Reaffirmed FY2022 guidance: sales $310-315M, gross margin 52-54%, adjusted EPS -$0.02 to $0.02.
- Post-quarter: FDA cleared AlphaVac F18 for venous use; IDE approved for pulmonary embolism; PRESERVE prostate trial enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122002826/0000914121-22-002826-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1275187/000091412122002826/an57733391-8ki.htm
  HTML page:      https://secwatch.observer/filing/0000914121-22-002826

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer